IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma

ABSTRACT: Type-2 inflammation is the most frequent endophenotype of asthma. Different biomarkers have been proposed to identify this inflammation because highly effective therapies have improved type-2 severe asthma control. We investigated the frequency of some biomarkers of type-2 inflammation (to...

Full description

Autores:

Sánchez Caraballo, Jorge Mario
Morales Cárdenas, Edison
Santamaría Salazar, Luis Carlos
Acevedo Vásquez, Ana Milena
Calle Álvarez, Ana María
Olivares Gómez, María Margarita
Gómez García, Carolina
Amaya Ruiz, Emerson Daniel
Cardona Villa, Ricardo

Tipo de recurso:

Article of investigation

Fecha de publicación:

2021

Institución:

Universidad de Antioquia

Repositorio:

Repositorio UdeA

Idioma:

eng

OAI Identifier:

oai:bibliotecadigital.udea.edu.co:10495/45014

Acceso en línea:

https://hdl.handle.net/10495/45014

Palabra clave:

Asma
Asthma
Biomarcadores
Biomarkers
Eosinófilos
Eosinophils
Inmunoglobulina E
Immunoglobulin E
Terapia Biológica
Biological Therapy
Prueba de Óxido Nítrico Exhalado Fraccionado
Fractional Exhaled Nitric Oxide Testing
https://id.nlm.nih.gov/mesh/D001249
https://id.nlm.nih.gov/mesh/D015415
https://id.nlm.nih.gov/mesh/D004804
https://id.nlm.nih.gov/mesh/D007073
https://id.nlm.nih.gov/mesh/D001691
https://id.nlm.nih.gov/mesh/D000089142

Rights

openAccess

License

http://creativecommons.org/licenses/by-nc-nd/2.5/co/